1. Anderson JM. Biological responses to materials. Annu Rev Mater Res 2001; 31: 81-110.

2. Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin Immunol 2008; 20:86-100.

3. Anderson JM. Mechanisms of inflammation and infection with implanted devices. Cardiovasc Pathol 1993; 2:199S-208S

4. Anderson JM. Inflammation and the foreign body response. Probl Gen Surg 1994; 11:17-160.

5. Anderson JM. Inflammatory response to implants. ASAIO J 1988; 11:101-107.

6. Anderson JM, Marchant RE. Tissue responses to drug delivery systems. In: Anderson JM, Kim SW, eds. Recent Advances in Drug-Delivery Systems. New York: Plenum Press, 1984:23-39.

7. Yamaguchi Y, Anderson JM. Biocompatibility studies of naltrexone sustained release formulations. J Control Release 1992; 19:299-314.

8. Yamaguchi K, Anderson JM. In vivo biocompatibility studies of Medisorb® 65/35 D,L-lactide/glycolide copolymer microspheres. J Control Release 1993; 24:81-93.

9. Anderson JM. In vivo biocompatibility of implantable delivery systems and biomaterials. Eur J Pharm Biopharm 1994; 40:1-8.

10. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997; 28:5-24.

11. Acute and chronic inflammation, tissue renewal and repair: regeneration, healing, and fibrosis. In: Kumar V, Abbas AK, Fausto N, eds. Pathologic Basis of Disease. 7th ed. Philadelphia: WB Saunders Company, 2005:47-118.

12. Gallin JI, Synderman R, eds. Inflammation: Basic Principles and Clinical Correlates. 2nd ed. New York: Raven Press, 1999.

13. Weissmann G, Smolen JE, Korchak HM. Release of inflammatory mediators from stimulated neutrophils. N Engl J Med 1980; 303:27-34.

14. Salthouse TN. Cellular enzyme activity at the polymer-tissue interface: a review. J Biomed Mater Res 1976; 10:197-229.

15. Clark RA, Lanigan JM, DellePelle P, et al. Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialization. J Invest Dermatol 1982; 79:264-269.

16. Tang L, Eaton JW. Fibrin(ogen) mediates acute inflammatory responses to biomaterials. J Exp Med 1993; 178:2147-2156.

17. Tang L. Mechanism of pro-inflammatory fibrinogen: biomaterial interactions. J Biomat Sci Polym Edn 1998; 9:1257-1266.

18. Riches DWF. Macrophage involvement in wound repair, remodeling, and fibrosis. In: Clark RAF, Henson PM, eds. The Molecular and Cellular Biology of Wound Repair. New York: Plenum Press, 1998:95-141.

19. Wahl SM, Wong H, McCartney FN. Role of growth factors in inflammation and repair. J Cell Biochem 1989; 40:193-199.

20. Dvorak HF, Harvey VS, Estrella P, et al. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 1987; 57:673-686.

21. Broadley KN, Aquino AM, Woodward SC, et al. Monospecific antibodies implicate basic fibroblast growth factor in normal wound repair. Lab Invest 1989; 61:571-575.

22. Sporn MB, Roberts AB. Peptide growth factors are multifunctional. Nature 1988; 332:217-219.

23. Muller G, Behrens J, Nussbaumer U, et al. Inhibitor action of transforming growth factor beta on endothelial cells. Proc Natl Acad Sci U S A 1987; 84:5600-5604.

24. Madri JA, Pratt BM, Tucker AM. Phenotypic modulation of endothelial cells by transforming growth factor-beta depends upon the composition and organization of the extracellular matrix. J Cell Biol 1988; 106:1375-1384.

25. Wahl SM, Hunt DA, Wakefield LM, et al. Transforming growth factor-beta (TGF-ß) induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987; 84:5788-5792.

26. Ignotz R, Endo T, Massague J. Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-beta. J Biol Chem 1987; 262:6443.

27. Marchant R, Hiltner A, Hamlin C, et al. In vivo biocompatibility studies: I. The cage implant system and a biodegradable hydrogel. J Biomed Mater Res 1983; 17:301-325.

28. Spilizewski KL, Marchant RE, Hamlin CR, et al. The effect of hydrocortisone acetate loaded poly(DL-lactide) films on the inflammatory response. J Control Release 1985; 2:197-203.

29. Ganz T. Neutrophil receptors. In: RI Lehrer, moderator. Neutrophils and Host Defense. Ann Intern Med 1988; 109:172-182.

30. Henson PM, Johnston RB Jr. Tissue injury in inflammation: oxidants, proteinases, and cationic proteins. J Clin Invest 1987; 79:669-674.

31. Malech HL, Gallin JL. Current concepts: immunology. Neutrophils in human diseases. N Engl J Med 1987; 317:687-694.

32. Jutila MA. Leukocyte traffic to sites of inflammation. APMIS 1992; 100:191-201.

33. Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation 1990; 50:537-544.

34. Cotran RS, Pober JS. Cytokine-endothelial interactions in inflammation, immunity, and vascular injury. J Am Soc Nephrol 1990; 1:225-235.

35. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69:11-25.

36. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991; 67:1033-1036.

37. Henson PM. The immunologic release of constituents from neutrophil leukocytes. II. Mechanisms of release during phagocytosis, and adherence to nonphagocytosable surfaces. J Immunol 1971; 107:1547-1557.

38. Henson PM. Mechanisms of exocytosis in phagocytic inflammatory cells. Am J Pathol 1980; 101:494-511.

39. Henson PM. The immunologic release of constituents from neutrophil leukocytes. I. The role of antibody and complement on nonphagocytosable surfaces or phag-ocytosable particles. J Immunol 1971; 107(6):1535-1546.

40. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320:365-376.

41. Paty PB, Greaff RW, Mathes SJ, et al. Superoxide production by wound neutrophils: evidence for increased activity of the NADPH oxidase. Arch Surg 1990; 125:65-69.

42. Johnston RB Jr. Monocytes and macrophages. N Engl J Med 1988; 318:747-752.

43. Williams GT, Williams WJ. Granulomatous inflammation—a review. J Clin Pathol 1983; 36:723-733.

44. Hulse GK, Stalenberg V, McCallum D, et al. Histological changes over time around the site of sustained release naltrexone-poly(DL-lactide) implants in humans. J Control Release 2005; 108:43-55.

45. Fielder PJ, Mortensen DL, Mallet P, et al. Differential long-term effects of insulin-like growth factor-I (IGF-I), growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats. Endocrinology 1996; 137:1913-1920.

46. Anderson JM, Langone JJ. Issues and perspectives on the biocompatibility and immunotoxicity evaluation of implanted controlled release systems. J Control Release 1999; 57:107-113.

47. Rice GP, Paszner B, Oger J, et al. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999; 52(6):1277-1279.

48. Meager A, Wadhwa M, Bird C, et al. Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease. Immunology 1999; 97(3):526-532.

49. Wadhwa M, Skog AL, Bird C, et al. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res 1999; 5(6):1353-1361.

50. Sporn MB, Roberts AB, eds. Peptide Growth Factors and Their Receptors I. New York: Springer-Verlag, 1990.

51. Fong Y, Moldawer LL, Shires GT, et al. The biologic characteristics of cytokines and their implication in surgical injury. Surg Gynecol Obstet 1990; 170:363-378.

Kovacs EJ. Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today 1991; 12:17-23.

Golden MA, Au YP, Kirkman TR, et al. Platelet-derived growth factor activity and RNA expression in healing vascular grafts in baboons. J Clin Invest 1991; 87:406-414. Mustoe TA, Pierce GF, Thomason A, et al. Accelerated healing of incisional wounds in rats induced by transforming growth factor. Science 1987; 237:1333-1336. Maciag T. Molecular and cellular mechanisms of angiogenesis. In: DeVita VT, Hellman S, Rosenberg S, eds. Important Advances in Oncology. Philadelphia: JB Lippincott, 1990:85-98.

Thompson JA, Anderson KD, DiPetro JM, et al. Site-directed neovessel formation in vivo. Science 1988; 241:1349-1352.

Ziats NP, Miller KM, Anderson JM. In vitro and in vivo interactions of cells with biomaterials. Biomaterials 1988; 9:5-13.

Rae T. The macrophage response to implant materials. Crit Rev Biocompat 1986; 2:97-126.

Greisler H. Macrophage-biomaterial interactions with bioresorbable vascular pros-theses. ASAIO Trans 1988; 34:1051-1057.

Chambers TJ, Spector WG. Inflammatory giant cells. Immunobiology 1982; 161: 283-289.

Anderson JM. Mutinucleated giant cells. Curr Opin Hematol 2000; 7:40-47. Haas A. The phagosome: compartment with a license to kill. Traffic 2007; 8:311-330. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005; 77:598-625. Segal AW. How neutrophils kill microbes. Annu Rev Immunol 2005; 23:197-223. Jankowski A, Scott CC, Grinstein S. Determinants of the phagosomal pH in neutrophils. J Biol Chem 2002; 277:6059-6066.

Silver IA, Murrills R, Etherington DJ. Microelectrode studies on the acid environment beneath adherent macrophages and osteoclasts. Exp Cell Res 1988; 175: 266-276.

Zhao Q, Agger MP, Fitzpatrick M, et al. Cellular interactions with biomaterials: in vivo cracking of pre-stressed Pellethane 2363-80A. J Biomed Mater Res 1990; 24: 621-637.

Zhao Q, Topham N, Anderson JM, et al. Foreign-body giant cells and polyurethane biostability: in vivo correlation of cell adhesion and surface cracking. J Biomed Mater Res 1991; 25:177-183.

Wiggins MJ, Wilkoff B, Anderson JM, et al. Biodegradation of polyether polyurethane inner insulation in bipolar pacemaker leads. J Biomed Mater Res 2001; 58: 302-307.

McNally AK, Anderson JM. Complement C3 participation in monocyte adhesion to different surfaces. Proc Natl Acad Sci U S A 1994; 91:10119-10123. McNally AK, Anderson JM. Interleukin-4 induces foreign body giant cells from human monocytes/macrophages. Differential lymphokine regulation of macrophage fusion leads to morphological variants of multinucleated giant cells. Am J Pathol 1995; 147:1487-1499.

Kao WJ, McNally AK, Hiltner A, et al. Role for interleukin-4 in foreign-body giant cell formation on a poly(etherurethane urea) in vivo. J Biomed Mater Res 1995; 29:1267-1276.

DeFife KM, McNally AK, Colton E, et al. Interleukin-13 induces human monocyte/ macrophage fusion and macrophage mannose receptor expression. J Immunol 1997; 158:319-328.

McNally AK, DeFife KM, Anderson JM. Interleukin-4-induced macrophage fusion is prevented by inhibitors of mannose receptor activity. Am J Pathol 1996; 149:975-985. Jenney CR, DeFife KM, Colton E, et al. Human monocyte/macrophage adhesion, macrophage motility, and IL-4-induced foreign body giant cell formation on silane-modified surfaces in vitro. J Biomed Mater Res 1998; 41:171-184. Jenney CR, Anderson JM. Effects of surface-coupled polyethylene oxide on human macrophage adhesion and foreign body giant cell formation in vitro. J Biomed Mater Res 1998; 44:206-216.

77. Jenney CR, Anderson JM. Alkylsilane-modified surfaces: inhibition of human macrophage adhesion and foreign body giant cell formation. J Biomed Mater Res 1999; 46:11-21.

78. Jones JA, Chang DT, Meyerson H, et al. Proteomic analysis and quantification of cytokines and chemokines from biomaterial surface-adherent macrophages and foreign body giant cells. J Biomed Mater Res 2007; 83A:585-596.

79. Jones JA, McNally AK, Chang DT, et al. Matrix metalloproteinases and their inhibitors in the foreign body reaction on biomaterials. J Biomed Mater Res 2008; 84A:158-166.

80. Anderson JM, Jones JA. Phenotypic dichotomies in the foreign body reaction. Biomaterials 2007; 28:5114-5120.

81. Chang DT, Jones JA, Meyerson H, et al. Lymphocyte/macrophage interactions: biomaterial surface-dependent cytokine, chemokine, and matrix protein production. J Biomed Mater Res A 2008; 87:676-687.

82. Anderson JM, Niven H, Pelagalli J, et al. The role of the fibrous capsule in the function of implanted drug-polymer sustained release systems. J Biomed Mater Res 1981; 15:889-902.

83. Schierholz JM. Drug delivery devices to enhance performance and improve outcome. Drug Deliv Syst Sci 2001; 1(2):52-56.

84. Daugherty AL, Cleland JL, Duenas EM, et al. Pharmacological modulation of the tissue response to implanted polylactic-co-glycolic acid microspheres. Eur J Pharm Biopharm 1997; 44(1637):89-102.

85. Lewis AL, Vick TA. Site-specific drug delivery from coronary stents. Drug Deliv Syst Sci 2001; 1(3):65-71.

86. Marx SO, Marks AR. The development of Rapamycin and its application to stent restenosis. Circulation 2001; 104:852-855.

87. Suzuki T, Kopia G, Hayashi S-I, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001; 104:1188-1193.

88. Richardson TP, Peters MC, Ennett AB, et al. Polymeric system for dual growth factor delivery. Nat Biotech 2001; 19:1029-1034.

89. Cleland JL, Daugherty A, Mrsny R. Emerging protein delivery methods. Curr Opin Biotechnol 2001; 12:212-219.

90. Babensee JE, McIntire LV, Mikos AG. Growth factor delivery for tissue engineering. Pharm Res 2000; 17(5):497-504.

91. Cleland JL, Duenas ET, Park A, et al. Development of poly-(D,L-lactid-coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. J Control Release 2001; 72:13-24.

92. Fischbach C, Mooney DJ. Polymers for pro- and anti-angiogenic therapy. Biomaterials 2007; 28:2069-2076.

93. Sands RW, Mooney DJ. Polymers to direct cell fate by controlling the microenvironment. Curr Opin Biotechnol 2007; 18:448-458.

94. Sun Q, Chen RR, Shen Y, et al. Sustained vascular endothelial growth factor delivery enhances angiogenesis and perfusion in ischemic hind limb. Pharm Res 2005; 22 (7):1110-1116.

95. Silva EA, Mooney DJ. Spatiotemporal control of vascular endothelial growth factory delivery from injectable hydrogels enhances angiogenesis. J Thromb Haemost 2007; 5:590-598.

96. Holland TA, Bodde EWH, Cuijpers V, et al. Degradable hydrogel scaffolds for in vivo delivery of single and dual growth factors in cartilage repair. Osteoarthritis Cartilage 2007; 15:187-197.

97. Hao X, Silva E, Mansson-Broberg A, et al. Angiogeneic effects of sequential release of VEGF-A(165) and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc Res 2007; 75:178-185.

98. Ennett AB, Kaigler D, Mooney DJ. Temporally regulated delivery of VEGF in vitro and in vivo. J Biomed Mater Res A 2006; 79A:176-184.

99. Daugherty AL, Rangell LK, Eckert R, et al. Sustained release formulations of rhVEGF165 produce a durable response in a non-compromised murine model of peripheral angiogenesis. (Personal communication.)

100. Holland TA, Tabata Y, Mikos AG. Dual growth factor delivery from degradable oligo(poly(ethylene glycol) fumarate) hydrogel scaffolds for cartilage tissue engineering. J Control Release 2005; 101(1-3):111-125.

101. Kim HK, Park TG. Comparative study on sustained release of human growth hormone from semi-crystalline poly(L-lactic acid) and amorphous poly(D,L-lactic-co-glycolic acid) microspheres: morphological effect on protein release. J Control Release 2004; 98:115-125.

102. Street J, Bao M, deGuzman L, et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad USA 2002; 99(15):9656-9661.

103. Maloney JM, Uhland SA, Polito BF, et al. Electrothermally activated microchips for implantable drug delivery and biosensing. J Control Release 2005; 109:244-255.

104. Prescott JH, Lipka S, Baldwin S, et al. Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device. Nat Biotech 2006; 24(4): 437-438.

105. Prescott JH, Krieger TJ, Lipka S, et al. Dosage form development, in vitro release kinetics, and in vitro-in vivo correlation for leuprolide released from an implantable multi-reservoir array. Pharm Res 2007; 24(7):1252-1261.

106. Proos ER, Prescott JH, Staples MA. Long-term stability and in vitro release of hPTH (1-34) from a multi-reservoir array. Pharm Res 2008; 25(6):1387-1395.

0 0

Post a comment